Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015 (2015), Article ID 430623, 5 pages
http://dx.doi.org/10.1155/2015/430623
Case Report

Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment

Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, China

Received 20 October 2014; Revised 28 February 2015; Accepted 9 March 2015

Academic Editor: Nelson Hamerschlak

Copyright © 2015 Xiaofan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Welniak, B. R. Blazar, and W. J. Murphy, “Immunobiology of allogeneic hematopoietic stem cell transplantation,” Annual Review of Immunology, vol. 25, pp. 139–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. R. E. Curtis, L. B. Travis, P. A. Rowlings et al., “Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study,” Blood, vol. 94, no. 7, pp. 2208–2216, 1999. View at Google Scholar · View at Scopus
  3. H. Khedmat and S. Taheri, “Ultra-early onset post-transplantation lymphoproliferative disease,” Saudi Journal of Kidney Diseases and Transplantation, vol. 24, no. 6, pp. 1144–1152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Frank, E. Cesarman, R. E. Michler, and D. M. Knowles, “Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus,” Blood, vol. 85, no. 5, pp. 1396–1403, 1995. View at Google Scholar · View at Scopus
  5. S. H. Swerdlow, “Classification of the posttransplant lymphoproliferative disorders: from the past to the present,” Seminars in Diagnostic Pathology, vol. 14, no. 1, pp. 2–7, 1997. View at Google Scholar · View at Scopus
  6. N. L. Harris, J. A. Ferry, and S. H. Swerdlow, “Posttransplant lymphoproliferative disorders: summary of society for hematopathology workshop,” Seminars in Diagnostic Pathology, vol. 14, no. 1, pp. 8–14, 1997. View at Google Scholar · View at Scopus
  7. I. N. M. Micallef, M. Chhanabhai, R. D. Gascoyne et al., “Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience,” Bone Marrow Transplantation, vol. 22, no. 10, pp. 981–987, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. D. E. Tsai, C. L. Hardy, J. E. Tomaszewski et al., “Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients,” Transplantation, vol. 71, no. 8, pp. 1076–1088, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Styczynski, L. Gil, G. Tridello et al., “Response to rituximab-based therapy and risk factor analysis in epstein barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the infectious diseases working party of the European Group for blood and marrow transplantation,” Clinical Infectious Diseases, vol. 57, no. 6, pp. 794–802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Doubrovina, B. Oflaz-Sozmen, S. E. Prockop et al., “Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation,” Blood, vol. 119, no. 11, pp. 2644–2656, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. H. E. Heslop, K. S. Slobod, M. A. Pule et al., “Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients,” Blood, vol. 115, no. 5, pp. 925–935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Leblond, N. Dhedin, M.-F. M. Bruneel et al., “Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 772–778, 2001. View at Google Scholar · View at Scopus
  13. M. Faraci, I. Caviglia, G. Morreale et al., “Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children,” Bone Marrow Transplantation, vol. 45, no. 6, pp. 1052–1055, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Faye, P. Quartier, Y. Reguerre et al., “Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children,” British Journal of Haematology, vol. 115, no. 1, pp. 112–118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. I. M. Ghobrial, T. M. Habermann, K. M. Ristow et al., “Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era,” Leukemia & Lymphoma, vol. 46, no. 2, pp. 191–196, 2005. View at Publisher · View at Google Scholar · View at Scopus